$PWP

Perella Weinberg Partners (PWP) Stock Jumps On Backlog Surge Despite Soft Earnings

Perella Weinberg Partners (PWP) shares rose about 18% to $17.65 after a reported backlog increase. The firm said first-half revenue was $305 million, down 17% year on year, while booked plus announced and pending mandates rose over 30%. Q2 revenue was roughly flat YoY, but net income and EPS declined; timing risk was cited for conversions into 2027.

Original reporting
Published Aug 2, 2026, 4:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 2, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Perella Weinberg Partners (PWP) Stock Jumps On Backlog Surge Despite Soft Earnings — source image
Decision brief

The 30-second read

$PWPBullishMed
01

Why it matters

Backlog momentum is presented as the primary driver of the sharp share move, while the bear case centers on weaker earnings and potential delays in converting announced mandates into revenue/earnings.

02

Market read

Traders are likely repricing the probability and timing of mandate-to-earnings conversion after the latest reported backlog metrics.

03

What to watch

Margin sensitivity is highlighted via a high compensation ratio and declining net income/EPS, which could offset backlog gains if deal economics weaken.

Relevance 6/10Novelty 5/10Timing: pre-market/early session reaction to the latest earnings print (Aug 2, 2026)

Background

The article frames Perella Weinberg Partners’ first-half results as mixed, with revenue down 17% YoY but backlog/mandates up materially.

Company-level read

Ticker impact

$PWPBullishMedium confidence
Context

PWP shares jumped 18% after the article says booked plus announced and pending mandates rose more than 30% despite softer revenue and earnings.

Expected impact

Near-term upside bias while investors price backlog conversion, but volatility risk remains if mandate timing slips.

Evidence & confidence

The text provides a concrete catalyst (18% jump) tied to a specific backlog metric (>30% increase) and contrasts it with weaker reported revenue (-17% YoY for first half) and declining Q2 net income/EPS plus explicit conversion timing risk.

Market effects

Reinforces that investment-advisory and capital-markets investors are trading backlog/mandate conversion more than near-term revenue prints.

Limited, company-specific read-through to US-listed capital markets/advisory firms.

Low, no cross-border deal or regulatory driver cited.

Counterpoint

The backlog surge may already be priced in given the article’s very high P/E (65.6x), and the conversion timing risk could cap follow-through.

Key entities

  • Perella Weinberg Partners

    US-listed advisory firm whose stock is reported to have jumped 18% on backlog growth despite soft earnings.

Related articles

$PWPMedAI 8/10

Why Perella Weinberg (PWP) Stock Is Trading Up Today

Perella Weinberg Partners (PWP) shares rose about 17.5% after the firm reported Q2 results. Adjusted EPS was $0.20 versus $0.06 expected and $0.09 a year earlier. Revenue was $156.5 million, flat year over year but 8.1% above expectations, with a 3.9% pre-tax margin. The stock remains below its 52-week high.

$PWPMedAI 8/10

Why is Perella Weinberg Partners stock surging today?

Perella Weinberg Partners (PWP) shares rose 19.3% after the firm reported Q2 results above lowered expectations. Adjusted EPS was $0.20 versus about $0.10 consensus, with revenue at $157 million, up 1% YoY. The article also cites promotions to partner and a $0.07 quarterly dividend, plus supportive sector and Fed backdrop.

$PWPMed

Perella Weinberg (NASDAQ:PWP) Delivers Impressive Q2 CY2026

Financial advisory firm Perella Weinberg Partners (NASDAQ: PWP) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $156.5 million. Its non-GAAP profit of $0.20 per share was significantly above analysts’ consensus estimates. Is now the time to buy Perella Weinberg? Find out by accessing our full research report, it’s free.

$PWPMed

Perella Weinberg Partners (PWP): Results of Operations and Financial Condition

Perella Weinberg Partners (PWP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026ex991-earningsrelease.htm EX-99.1 Document Exhibit 99.1 Perella Weinberg Reports Second Quarter 2026 Results Financial Overview - Second Quarter • Revenues of $157 Million, Up 1% From a Year Ago • GAAP Pre-Tax Income of $6 Million, Adjusted Pre-Tax Income of $27 M

$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

$ONMed

The Numbers Behind ON Semiconductor’s (ON) Higher Target and Unchanged Hold Rating

ON Semiconductor (NASDAQ:ON) reported stronger-than-expected Q2 earnings and issued Q3 guidance above Wall Street expectations. Robert W. Baird analyst Tristan Gerra raised his price target to $108 from $100 and kept a Neutral rating, citing improving AI data center, industrial, EV and China trends and gross margin guidance of 40% to 42%. He flagged potential market-share losses versus TXN and ST.